Potential prognostic factor in alternating electric fields therapy based on absorbed energy in tissue
Source abstract
Abstract
The present study aimed to determine a method for estimating a potential prognostic factor in alternating electric fields for the treatment of solid tumors based on cell survival curves that evaluate cell proliferation capability. In AGS, B16F10, U373, and HPAF-II cancer cell lines, the proportional relationships of the electric field magnitude and the duration of application with the proliferation of cancer cell lines was identified by in vitro alternating current electric field experiments performed under various conditions. A prognostic factor applicable to alternating electric field therapy was developed by identifying proportional relationships of the electric field magnitude and the duration of application with the proliferation of the four cancer cell lines. Through the experimental results, the absorbed energy in tissue has been suggested as a potential prognostic factor in alternating electric field therapy. The absorbed energy in tissue can be used as a reference to quantify the inhibition of cell proliferation related to control, enabling systematic assessment of alternating electric field therapy which, to date, has not been possible.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: 3D Printing in Biomedical Research · Microbial Inactivation Methods · Planarian Biology and Electrostimulation
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Bioengineering, Korea University 1 , Seoul 02841, Republic of Korea
Institute of Global Health Technology (IGHT), Korea University 2 , Seoul 02841, Republic of Korea
Department of Internal Medicine, Anam Hospital, Korea University College of Medicine 3 , Seoul 02841, Republic of Korea
FieldCure Ltd. 4 , Seoul 02852, Republic of Korea
Funding
National Research Foundation of Korea · Korea University
References (14)
Show source-provided references
1. Cancer Res. · 2004 · 64 · 328810.1158/0008-5472.can-04-0083 ↗
2. Expert Opin. Invest. Drugs · 2011 · 20 · 109910.1517/13543784.2011.583236 ↗
3. Front. Oncol. · 2020 · 10 · 57599210.3389/fonc.2020.575992 ↗
4. Proc. Natl. Acad. Sci. U. S. A. · 2007 · 104 · 1015210.1073/pnas.0702916104 ↗
5. Cancers · 2019 · 11 · 17410.3390/cancers11020174 ↗
6. Int. J. Radiat. Oncol., Biol., Phys. · 2019 · 104 · 110610.1016/j.ijrobp.2019.04.008 ↗
7. Technol. Cancer Res. Treat. · 2019 · 18 · 153303381984500810.1177/1533033819845008 ↗
8. Int. J. Radiat. Oncol., Biol., Phys. · 2022 · 112 · 126910.1016/j.ijrobp.2021.12.152 ↗
9. ACS Appl. Mater. Interfaces · 2015 · 7 · 2679210.1021/acsami.5b08863 ↗
10. 2014
11. J. Visualized Exp. · 2017 · 123 · e5582010.3791/55820 ↗
12. Cell Death Discovery · 2018 · 4 · 4610.1038/s41420-018-0106-x ↗
13. Sci. Rep. · 2016 · 5 · 1804610.1038/srep18046 ↗
14. Cell Death Discovery · 2018 · 4 · 11310.1038/s41420-018-0130-x ↗